Skip to content

Systematic Laryngoscopic Evaluation of Upper Airways in Ventilated ALS Patients in Portugal and in Norway

Systematic Laryngoscopic Evaluation of Upper Airways in Ventilated Amyotrophic Lateral Sclerosis (ALS) Patients in Portugal and in Norway

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03887338
Enrollment
60
Registered
2019-03-22
Start date
2019-03-21
Completion date
2022-12-31
Last updated
2021-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Keywords

Noninvasive Ventilation, Laryngoscopy

Brief summary

The study examines if titration of Non-Invasive mechanical ventilation (NIV) settings during ongoing laryngoscopic visualization can improve the compliance of NIV in subjects with Amyotrophic Lateral Sclerosis (ALS). The study is a multicentre study between Norwegian National Advisory Unit on Long-term Mechanical Ventilation at the Thoracic Department, Haukeland University Hospital, Bergen, Norway and Centro Hospital Tras-os-Montes e Alto Douro, Vila Real, Portugal.

Detailed description

ALS, amyotrophic lateral sclerosis, is a rare and fatal disease causing gradual loss of motor neurons and thus loss of function in all skeletal muscle, eventually also in the breathing muscles, leading to respiratory failure and ultimately death. There is no causal treatment. The treatment provided aims to improve life quality as long as possible. Non-invasive ventilation (NIV) compensates for respiratory failure as breathing deteriorates. ALS patients with bulbar innervated muscle dysfunction (mouth, tongue, jaw, throat, larynx) have poor compliance to the use of NIV. It is not completely understood why bulbar ALS patients fails NIV, although the upper airways have been a suggested cause also of this treatment failure. The investigators in the Norwegian study group has previously examined laryngeal response patterns (using transnasal fiberoptic laryngoscopy ) during mechanically assisted cough in ALS. The studies revealed that Transnasal fiberoptic laryngoscopy was safely performed with ongoing mechanically assisted cough, and it appeared a feasible tool to visualize the laryngeal responses to mechanical cough therapy. The further hypothesis is that the use of transnasal fiberoptic laryngoscopy during ongoing NIV titration could improve the compliance of NIV treatment in ALS. Since ALS is a relatively rare disease and it is difficult to perform large clinical studies, a project group has been established and agreed to a common protocol of a population-based multicenter-study including two hospitals, in Bergen in Norway and Vila Real in Portugal. Aims of the study are: To investigate the feasibility of video-recorded Transnasal fiberoptic laryngoscopic evaluation of the upper airways applied during NIV titration, and to describe the upper airway responses to NIV treatment in patients with ALS. To explore whether the endoscopic view of the upper airways will influence the titration of NIV settings in ALS patients. To explore whether NIV titration with endoscopic evaluation will influence NIV compliance and ventilation effectiveness in ALS patients.

Interventions

Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.

Sponsors

University of Trás-os-Montes and Alto Douro
CollaboratorOTHER
Universidade do Porto
CollaboratorOTHER
Haukeland University Hospital
CollaboratorOTHER
Tiina Maarit Andersen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

All the subjects will receive the same intervention, and they will be examined both prior to the intervention, one month after and three months after the intervention. They will act as they own controls.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed Amyotrophic Lateral Sclerosis (ALS) due to El Escorial criteria * Must have already established Non-invasive ventilation (NIV)

Exclusion criteria

* Ages under 18 years * Unstable ischemic heart disease * Oncological disease * Ventilatory support dependency (more than 16h per day)

Design outcomes

Primary

MeasureTime frameDescription
Apnoea-hypopnea index (AHI)Baseline, one and three months after the intervention.Change in number of apnea and hypopnea events per hour of sleep
NIV LeaksBaseline, one and three months after the intervention.Change in median and 95%
NIV time of useBaseline, one and three months after the intervention.Change in % of time of use \> than 4 hours/day
NIV complianceBaseline, one and three months after the intervention.Change in number of interruptions, complains and ventilator adjustments
Time of NIV useBaseline, one and three months after the intervention.Change in median daily and average daily of hours, minutes

Secondary

MeasureTime frameDescription
Night-time capnographyBaseline, one and three months after the intervention.Change in concentration or partial pressure of carbon dioxide in the respiratory gases
Night-time pulseoximeterBaseline, one and three months after the intervention.Change in oxygen saturation of patients blood

Countries

Norway, Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026